A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

[1]  E. Oki,et al.  REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. , 2019 .

[2]  F. Rojo,et al.  Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer , 2018, British Journal of Cancer.

[3]  J. Tabernero,et al.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Tabernero,et al.  Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Bramlett,et al.  Abstract 739: Orthogonal validation of oncomine cfDNA panel data with digital PCR using TaqMan Rare Mutation Assays , 2017 .

[6]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. Salazar,et al.  Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Fox,et al.  Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing , 2017, Molecular oncology.

[9]  C. Bokemeyer,et al.  FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, European journal of cancer.

[10]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Muro,et al.  Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study , 2015, EBioMedicine.

[12]  J. Thiery,et al.  Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib , 2015, Journal of Translational Medicine.

[13]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[14]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[15]  K. Kinzler,et al.  Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.